Cargando…
Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study
BACKGROUND: The EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study was an international, randomized, open-label, assessor-blinded, parallel-group study assessing the efficacy and tolerability of interferon (IFN) beta-1a, 44 mcg subcutaneously (sc) thr...
Autores principales: | Traboulsee, A, AL-Sabbagh, A, Bennett, R, Chang, P, Li, DKB |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374794/ https://www.ncbi.nlm.nih.gov/pubmed/18426595 http://dx.doi.org/10.1186/1471-2377-8-11 |
Ejemplares similares
-
Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1
por: Traboulsee, Anthony, et al.
Publicado: (2018) -
Subcutaneous interferon β-1a three times weekly and the natural evolution of gadolinium-enhancing lesions into chronic black holes in relapsing and progressive multiple sclerosis: Analysis of PRISMS and SPECTRIMS trials
por: Traboulsee, A, et al.
Publicado: (2017) -
Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013) -
Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
por: Cocco, Eleonora, et al.
Publicado: (2015) -
The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis
por: Madsen, Claus
Publicado: (2017)